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Intestinal Epithelial Cell-Specific 
Deletion of PLD2 Alleviates DSS-
Induced Colitis by Regulating 
Occludin
Chaithanya Chelakkot1, Jaewang Ghim2,3, Nirmal Rajasekaran4, Jong-Sun Choi5, Jung-Hwan 
Kim1, Myoung Ho Jang1, Young Kee Shin4,5, Pann-Ghill Suh6 & Sung Ho Ryu1,2
Ulcerative colitis is a multi-factorial disease involving a dysregulated immune response. Disruptions to 
the intestinal epithelial barrier and translocation of bacteria, resulting in inflammation, are common in 
colitis. The mechanisms underlying epithelial barrier dysfunction or regulation of tight junction proteins 
during disease progression of colitis have not been clearly elucidated. Increase in phospholipase D 
(PLD) activity is associated with disease severity in colitis animal models. However, the role of PLD2 
in the maintenance of intestinal barrier integrity remains elusive. We have generated intestinal-
specific Pld2 knockout mice (Pld2 IEC-KO) to investigate the mechanism of intestinal epithelial PLD2 
in colitis. We show that the knockout of Pld2 confers protection against dextran sodium sulphate 
(DSS)-induced colitis in mice. Treatment with DSS induced the expression of PLD2 and downregulated 
occludin in colon epithelial cells. PLD2 was shown to mediate phosphorylation of occludin and induce 
its proteasomal degradation in a c-Src kinase-dependent pathway. Additionally, we have shown that 
treatment with an inhibitor of PLD2 can rescue mice from DSS-induced colitis. To our knowledge, this is 
the first report showing that PLD2 is pivotal in the regulation of the integrity of epithelial tight junctions 
and occludin turn over, thereby implicating it in the pathogenesis of colitis.
Ulcerative colitis (UC) is a multi-factorial disease with genetic, immunological, environmental, and diet-related 
factors contributing to its etiology1, 2. Incidence of UC is increasing worldwide, and current research is focused 
on elucidating the origin and mechanism of disease initiation and perpetuation. A chronically dysregulated 
response, mediated by the host’s immune cells against normal gut microbiota, results in severe inflammation and 
is the hallmark of UC3. Genome-wide association studies have revealed several genes associated with UC. These 
studies have highlighted the role of immune cell- and intestinal barrier-associated genes in the development of 
UC; however, convincing evidence, enabling the understanding of the complex aetiology of UC, is still lacking4.
Maintenance of proper barrier integrity is an essential function of the epithelial layer. Disruptions in the intes-
tinal epithelial monolayer lead to bacterial translocation across the membrane and subsequent inflammation5. 
Patients with UC show an increased intestinal permeability6, 7. Tight junction proteins are a major class of pro-
teins responsible for junctional sealing and selective transport of molecules across the epithelial barrier4, 8. Altered 
or compromised expression of epithelial tight junction proteins is a key factor in the pathogenesis of the disease9, 
10. However, the mechanisms underlying epithelial barrier dysfunction or regulation of epithelial tight junction 
proteins during disease progression remain unexplored.
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PLD2 is a well-characterized signalling mediator that regulates several cellular events. The classic function 
of PLD2 is to catalyse the hydrolysis of phosphatidylcholine to phosphatidic acid (PA), which acts as a second 
messenger. Various cellular stimuli can activate PLD2 to generate PA, which in turn mediates a plethora of cel-
lular events and signalling pathways, depending on the stimuli and cellular context11, 12. PLD2 is an essential 
player in epithelial cell migration, reorganization of the actin cytoskeleton, and secretion13–16. Recent studies 
highlight the pathophysiological role of PLD2 in the pathogenesis of several diseases17–21. Sakamoto et al. (2000) 
reported that PLD activity positively correlates with the disease damage score in acetic acid-induced colitis in 
rats. Similar results were also shown by mRNA expression profiling from the mucosal samples of patients with 
UC22, 23. However, these studies do not provide direct evidence for the role of PLD in colitis. Neutrophil PLD2 
plays a role in the pathogenesis of UC20; while, the role of intestinal epithelial PLD2 remains unclear. In this study, 
we aimed to identify the role of intestinal epithelial PLD2 in the pathogenesis of UC. For this purpose, we used 
tissue specific knockout mice in a DSS-induced model of experimental colitis. We found that knocking out Pld2 
in intestinal epithelium alleviated the symptoms of colitis in mice. Our study highlights a novel role of PLD2 in 
the regulation of tight junction protein occludin and intestinal barrier integrity.
Results
Intestinal epithelial knockout of Pld2 protects mice from developing experimental colitis. Few 
studies have examined the role of intestinal PLD2 in DSS-induced colitis using expression profiling data from 
patients with UC and animal models of PLD activity20, 22, 23. To investigate the changes in the expression of PLD2 
in the pathogenesis of colitis, we orally fed C57BL/6 mice with 2% DSS for 7 days and analysed PLD2 expres-
sion in whole intestinal lysates. Treatment with DSS induced PLD2 expression (Supplementary Fig. S1A). This 
increase in PLD2, got us speculate that PLD2 might be playing a role in the pathogenesis of DSS-induced colitis. 
To examine the mechanism of intestinal epithelial PLD2 in DSS-induced colitis, we generated intestine-specific 
Pld2 knockout (Pld2 IEC KO) mice by mating Pld2 floxed mice with Villin-Cre mice (Supplementary Fig. S1B). 
Deletion of Pld2 in the intestinal epithelial cells was confirmed by checking the protein expression of PLD2 
in colon tissue samples using immunohistochemistry (Supplementary Fig. S1C). To generate an experimental 
colitis model, Pld2 IEC KO mice, and their floxed littermates, were given 2% DSS in drinking water for 10 days. 
Throughout this period, the clinical parameters of DSS-induced colitis, including weight loss, rectal bleeding, 
and stool consistency, were monitored. DSS-induced weight loss was significantly reduced in Pld2 IEC KO mice 
when compared with DSS-treated WT (control) mice (Fig. 1A). The cumulative clinical score index indicated that 
disease manifestation was less severe in Pld2 IEC KO mice compared to control mice (Fig. 1D). Mice were then 
euthanized and the colon was dissected to analyse its pathological features. Consistent with the clinical score data, 
the colon of Pld2 IEC KO was longer than that of the control mice (Fig. 1B and C). To assess the effect of the Pld2 
knockout on the survival rate, control and Pld2 IEC KO mice were continuously treated with DSS and monitored 
for DSS-induced mortality. Control mice had significantly lower survival rate compared to Pld2 IEC KO mice, 
which suggests that intestine-specific ablation of Pld2 plays a protective role in DSS-induced colitis (Fig. 1E). 
Analysis of morphology of colon tissue samples by hematoxylin and eosin staining revealed that the intestinal 
epithelial layer was severely damaged in the control mice, which showed extensive loss of crypt structures and 
increased recruitment of immune cells compared to the Pld2 IEC KO mice. Cumulative scoring of histological 
data demonstrated a lower injury score in Pld2 IEC KO mice compared to the control mice (Fig. 1F,G). Analysis 
of histological sections, at different time points during treatment, showed a significant difference in the damage 
induced in control and IEC KO mice as early as day 6 (Supplementary Fig. S2A). Quantitative PCR analysis of 
inflammatory cytokines, obtained from isolated intestinal cells, showed that the cytokine level was significantly 
lower in Pld2 IEC KO mice than in the control mice (Supplementary Fig. S2B). These findings suggest that the 
knockout of Pld2 protected the Pld2 IEC KO mice from developing DSS-induced colitis.
Next, we examined whether the protective role of intestinal PLD2 knockdown is limited to DSS-induced 
colitis, by using a dinitrobenzene sulphonic acid (DNBS)-induced colitis model24. PLD2 IEC-KO mice showed 
less severe symptoms of colitis after intrarectal administration of 200 mg/kg of DNBS in 35% ethanol. The clinical 
phenotypes (Fig. 2A–D), indicative of disease manifestation, and the histological score (Fig. 2E,F) used to assess 
the extent of colon damage, showed that the knockdown of PLD2 confers protection against the development of 
DNBS-induced colitis, and that this protective action is neither specific nor limited to one colitis model.
Pld2 IEC KO mice have increased barrier integrity and increased expression of occludin in the 
intestine. The loss of intestinal barrier integrity is a common feature in DSS-induced colitis3. Histological 
analysis of colon tissue samples showed significant differences in damage induced in the epithelial layer. Based 
on these results, we hypothesized that there may be differences in the permeability of the intestinal barrier 
between the control and Pld2 IEC KO mice. An in-vivo permeability assay, using FITC-dextran, showed that 
the intestinal barrier permeability was higher in the control mice compared to the Pld2 IEC KO mice (Fig. 3A). 
An altered expression of tight junction proteins is closely associated with epithelial barrier integrity and colitis25, 
26. We analysed the expression of major tight junction proteins in colon epithelial cells of DSS-treated control 
and IEC KO mice. We observed an increased level of occludin in the colon tissue samples of Pld2 IEC KO mice 
when compared with the control mice, as shown by immunohistochemistry and western blot data (Fig. 3B–D, 
Supplementary Fig. S1D). This result suggests that the intestinal barrier integrity was relatively intact in Pld2 IEC 
KO mice even after treatment with DSS.
PLD2 is involved in the downregulation of occludin in intestinal epithelial cells. As DSS induced 
the expression of PLD2 in-vivo, we checked whether similar changes would occur in-vitro also. Treatment with 
DSS induced PLD2 expression in HT29 colon epithelial cells. Consistent with previous results, a decrease in 
occludin expression was observed upon PLD2 upregulation in the DSS-treated colon epithelial cells (Fig. 4A). 
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Because occludin expression was higher in Pld2 IEC KO mice (Supplementary Fig. S3A), we examined whether 
PLD2 is involved in occludin turnover. Small interference RNA (siRNA)-mediated Pld2 knockdown in colon epi-
thelial cell lines increased occludin expression, consistent with our in-vivo data from Pld2 IEC KO mice (Fig. 4B). 
We assessed the expression of occludin after the Pld2 knockdown in DSS-treated HT-29 colon epithelial cells and 
found that DSS induced occludin down regulation was rescued after Pld2 knockdown, which was not observed 
in control siRNA treated cells (Supplementary Fig. S3B). Overexpression of PLD2 in HT-29 colon epithelial cells 
Figure 1. Intestinal epithelial-specific knockout of PLD2 alleviates the symptoms of DSS-induced colitis in 
mice. (A) Changes in the body weights of IEC KO mice, compared with those of the control animals, during 
treatment with DSS. Mice were administered 2% v/w DSS in drinking water for the indicated number of days, 
and body weight was measured every day. (B,C) Gross imaging of colons dissected from IEC KO and control 
mice. The colon length of IEC KO mice and control mice after 10 days of treatment with DSS. (D) Clinical 
scoring of DSS-induced colitis in the control and IEC-KO mice. (E) Survival rate of IEC KO and control mice 
with colitis. The survival of the mice was scored daily; survival rate was analysed using the Kaplan-Meier test 
and is shown as the percentage of the total number of mice. (F) Hematoxylin and eosin (H&E) staining of 
colon sections from the control and IEC KO mice, dissected at the indicated day. (G) Histological score of 
H&E-stained sections of colon tissue. Scale bar: 200 µm, 20 µm. All data are shown as mean ± SEM. *p < 0.05, 
**p < 0.01.
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showed decreased occludin expression, confirming that the expression of PLD2 and occludin are inversely cor-
related (Fig. 4C).
Additionally, we analysed the functional relevance of Pld2 inhibition on cultured Caco2 monolayer cells, a 
colon epithelial cell line that can differentiate upon contact and form a monolayer that resembles an in-vivo intes-
tinal epithelial layer. Initially, we evaluated whether the response of Caco2 cells to DSS treatment is similar to that 
of the HT-29 cells. For this, we treated Caco2 cells with 2% DSS and observed that PLD2 expression increased 
in Caco2 cells with a corresponding downregulation in the levels of occludin, which was similar to the response 
in HT-29 cells. We also observed an inverse relationship between PLD2 and occludin expression in Caco2 cells 
(Supplementary Fig. S4). The functional relevance of PLD2 in intestinal barrier integrity was demonstrated by 
Figure 2. Intestinal epithelial-specific PLD2 deletion protects mice from the development of dinitrobenzene 
sulphonic acid (DNBS)-induced colitis. (A) Body weight change in control and IEC-KO mice after treatment 
with DNBS. Mice were given a single intra-rectal administration of 200 mg/kg DNBS in 35% ethanol, and body 
weight was measured every day. (B) Gross imaging of the colons after treatment with DNBS in control and 
IEC-KO mice. (C) Colon length in the control and IEC-KO mice after treatment with DNBS for 4 days. (D) 
Clinical score of the control and IEC-KO mice after DNBS treatment. (E) H&E staining of the colon tissue from 
the control and IEC-KO mice. (F) Histological scoring in control and IEC-KO mice after challenge with DNBS. 
Scale bar: 200 µm, 20 µm. All data are shown as mean ± SEM. *p < 0.05, **p < 0.01.
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an in-vitro permeability assay. The DSS-induced loss of barrier integrity, shown by FITC leakage into the lower 
chamber, was rescued by inhibition of Pld2 using a small molecule inhibitor VU0364739.HCl (Fig. 4D). Similarly, 
the dissociation of occludin from the membrane, which was induced using DSS treatment, was recovered upon 
inhibition of Pld2, as shown by immunocytochemistry (Fig. 4E). These findings are in agreement with our pro-
posed protective role of PLD2 ablation in the DSS-induced change in barrier integrity. Taken together, our data 
show that DSS treatment can induce PLD2 expression in colon epithelial cells, which results in the downregula-
tion of the tight junction protein occludin.
PLD2 mediates the degradation of occludin via occludin phosphorylation induced by 
c-Src. Next, we investigated the mechanism by which PLD2 may contribute to occludin turnover. Quantitative 
real time-PCR showed that treatment with DSS does not affect the level of occludin mRNA in-vitro or in-vivo, 
which rules out regulation at the transcriptional level (Supplementary Fig. S5). To ascertain the mechanism of 
occludin downregulation during treatment with DSS, we treated HT-29 colon epithelial cells with cycloheximide 
(10 µg/mL) and MG132 (10 µM), which are inhibitors of translation and proteasome degradation, respectively. 
No significant difference was found in the occludin level after treatment with MG132 in DSS-treated Pld2 knock-
down cells compared with those in the untreated group, which shows that the translation rate of occludin was not 
altered by treatment with DSS (Fig. 5A). Inhibiting translation with cycloheximide (CHX) significantly reduced 
occludin expression in the control cells, whereas occludin levels were constant in the Pld2 knockdown cells after 
treatment with DSS (Fig. 5B); this indicates that treatment with CHX caused a difference in the degradation 
rate of occludin. Hence, we conclude that occludin downregulation occurs during the post-translational step of 
degradation.
Reversible phosphorylation of occludin, and other tight junction proteins, is critical for barrier integrity. The 
highly dynamic nature of occludin phosphorylation is a predominant mechanism in occludin turnover. Occludin 
is extensively phosphorylated at the serine/threonine (Ser/Thr) residues in its basal state, a modification essential 
for its maintenance at membrane junctions. Reduction in phosphorylation at these sites, combined with increased 
tyrosine (Tyr) phosphorylation, result in occludin dissociating from the membrane and its proteasome-mediated 
degradation27, 28. Occludin levels, examined using immunoprecipitation, and the levels of phosphorylated 
Figure 3. Intestine-specific knockdown of PLD2 decreases occludin expression in mice. (A) In-vivo 
permeability assay in control and IEC KO mice, conducted after 4 hours of treatment with FITC-dextran, 
administered by oral gavage. FITC concentration in the serum was measured using a spectrofluorometer 
and is shown as the mean ± SEM. (B) Immunohistochemistry assessing the expression of occludin in the 
paraformaldehyde-fixed paraffin-embedded sections of colon tissue from control and IEC KO mice. Scale bar 
is 50 µm. (C) Western blots of occludin in isolated colon epithelial cells from the control and IEC KO mice. (D) 
Associated western blot quantification. All data are shown as the mean ± SEM. *p < 0.05.
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Figure 4. PLD2 is involved in DSS-induced downregulation of occludin. (A) Western blots showing the effect 
of DSS treatment on the level of PLD2 in HT-29 colon epithelial cells at the indicated time points. Quantitative 
data showing the relative PLD2 and occludin expression at 8, 12, and 24 hours. (B) Effects of siRNA-mediated 
PLD2 knockdown in HT-29 colon epithelial cells (C) HT-29 colon epithelial cells were transfected with control, 
or PLD2 vector and PLD2, and occludin expression was analysed at 48 and 72 hours. Graph showing relative 
protein expression. Panel A–C: PLD2 expression of untreated (NT) vs. the indicated time point, or specified 
treatment group (*p < 0.05, **p < 0.01); occludin expression in NT vs. the indicated time point or specified 
treatment group (#p < 0.05, ##p < 0.01). Uncropped western images are shown in the Supplementary Fig. S6. (D) 
In-vitro intestinal permeability assay using Caco-2 monolayer culture. Data are represented as the concentration 
of FITC in μg/ml. (E) Immunocytochemistry assessing the expression of occludin in a confluent Caco-2 
monolayer culture treated with DSS, or DSS + PLD2 inhibitor. Scale bar is 10 µm. Bar graph shows the mean 
fluorescence intensity. All data are represented as the mean ± SEM. *p < 0.05.
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Figure 5. PLD2 regulates occludin levels by mediating the proteasome-mediated degradation of occludin via 
a Src kinase-dependent pathway. (A) HT-29 cells transfected with PLD2 siRNA were treated with 2% DSS and 
10 nM MG132 to inhibit protein degradation; PLD2 and occludin expression were analysed by western blotting 
at the indicated time points. (B) HT-29 cells, transfected with control PLD2 siRNA, were treated with 2% 
DSS and 10 µg/mL cycloheximide (CHX) to inhibit protein degradation; PLD2 and occludin expression were 
analysed by western blotting at the indicated time points. (C) Occludin was immunoprecipitated after HT-29 
colon epithelial cells were treated with 2% DSS; cell lysates were immunoblotted for phospho-tyrosine to assess 
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tyrosine, assessed using western blotting, showed that even during DSS-induced occludin downregulation, there 
was a significant increase in tyrosine phosphorylation (Fig. 5C).
Several kinases phosphorylate occludin29, 30. The Src family kinases are involved in the regulation of tight 
junctions; however, whether Src kinase-mediated tyrosine phosphorylation results in the assembly or disassem-
bly of tight junction is still unclear. Treating HT-29 cells with DSS upregulated c-Src expression (Fig. 5D). To 
test whether PLD2-dependent Src activation is required for occludin downregulation, we assessed the expres-
sion of occludin and c-Src in siRNA-mediated Pld2 knockdown cells. Pld2 knockdown significantly reduced 
DSS-induced c-Src phosphorylation and rescued occludin levels (Fig. 5E). Treatment with 1 µM c-Src kinase 
inhibitor (PP2) rescued occludin degradation when co-administered with DSS (Fig. 5F). Our results suggest that 
DSS-induced phosphorylation, and degradation of occludin by c-Src kinase, is mediated by PLD2, making PLD2 
a crucial player in the DSS-induced regulation of tight junctions.
Pld2 inhibitor alleviates the symptoms of DSS-induced colitis in mice. To validate the 
effect of PLD2 inhibition on the development of colitis, we co-treated wild type mice with DSS and 10 mg/
kg of VU0364739.HCl, which is a chemical inhibitor of Pld2; we then monitored the clinical phenotype of 
DSS-induced colitis. Similar to Pld2 IEC KO mice, disease manifestation was less severe when Pld2 inhibitor 
was co-administered with DSS. The control group, which received the Pld2 inhibitor alone, did not display 
clinical or pathological phenotypes. The DSS + Pld2 inhibitor-treated mice were protected from rapid weight 
loss, in contrast to the group treated with DSS alone, which exhibited significant weight loss (Fig. 6A). The 
clinical damage score, which was assessed by checking the stool consistency and presence of blood in the 
stool, was also significantly lower in the DSS + Pld2 inhibitor-treated mice compared to the mice treated with 
DSS alone (Fig. 6D). DSS + Pld2 inhibitor-treated mice also had comparatively longer colons (Fig. 6B,C). The 
histogram data and histological score clearly showed that the crypt structure of DSS + Pld2 inhibitor-treated 
mice was more intact, with lesser damage to the intestinal barrier and less inflammation-related immune cells 
recruited into the crypts (Fig. 6E,F). Our findings show that Pld2 inhibition was sufficient to rescue mice from 
the deleterious effect of DSS.
Discussion
Recent studies indicate that PLD2 plays a role in pathological conditions. Studies, using conditional knockout 
mice, have identified previously unknown functions of PLD2 in the pathology of several diseases. To our knowl-
edge, the role of epithelial PLD2 in colitis pathogenesis has not been previously detailed. We demonstrate that 
genetic ablation of intestinal epithelial PLD2 prevents DSS-treated mice from developing colitis by improving 
the intestinal integrity. Similarly, chemical inhibition of PLD2 in-vitro, using differentiated monolayer cultures 
of Caco2 cells, reduced DSS-induced barrier permeability. We show that PLD2 downregulates the tight junction 
protein occludin and mediates the regulation of intestinal permeability by mediating the turnover of occludin. 
Thus, we show that PLD2 plays a role in the pathology of experimental colitis by influencing the maintenance of 
epithelial barrier integrity in the intestinal epithelial cells. We investigated whether the protective role of PLD2 is 
specific to DSS-induced colitis, or is a general mechanism also active in other models as well as in colitis patho-
genesis in humans. Hence, we used a DNBS-induced colitis model to evaluate whether PLD2 affects other experi-
mental colitis models. Our results (Fig. 2) show that IEC-KO mice had less severe symptoms of colitis, indicating 
a protective role of PLD2 in the hapten-induced colitis model. However, further studies involving human tissue 
samples are necessary to determine the role of epithelial PLD2 in clinical pathogenesis and disease perpetuation.
Sealing tight junction proteins is important in tight junction stability and maintaining the intestinal epithe-
lial barrier29, 31. Alterations in tight junction proteins have severe clinical implications32. Occludin is a major 
tight junction protein, playing a critical role in regulating the paracellular permeability; alteration in occludin 
levels is associated with intestinal permeability33. Patients with active Crohn’s disease, a type of inflammatory 
bowel disorder, show downregulated levels of occludin and severely compromised tight junction integrity9, 34. 
A reduced level of occludin occurs in patients with irritable bowel syndrome (IBS)35. In our IEC KO mice, the 
DSS-induced reduction in occludin levels was recovered, indicating that PLD2 regulates the expression of occlu-
din after treatment with DSS. The knockdown and overexpression of Pld2 show an inverse relationship between 
PLD2 and occludin (Fig. 4). Several mechanisms of occludin regulation have been reported29, 36, 37. In endothelial 
cells, PLD2 downregulates occludin via the Raf-1 dependent pathway and induces endothelial permeability38. 
However, the mechanism of occludin regulation by PLD2 in intestinal epithelial cells is not widely studied. IEC 
KO or control mice, treated with DSS, did not show an altered level of occludin mRNA, ruling out regulation 
at the transcriptional level. Our data, using CHX and MG132, showed that PLD2 regulates occludin levels by 
the level of phospho-occludin at the indicated time points. PLD2 and occludin expression is shown. (D) HT-29 
cells were treated with 2% DSS and the expression of PLD2, occludin, c-Src kinase, and phosphor c-Src kinase, 
at the specified time points, was analysed using western blotting. PLD2 expression: *p < 0.05, **p < 0.01; 
occludin expression: #p < 0.05, ##p < 0.01; c-Src expression: ‡p < 0.05, ‡‡p < 0.01; phosphor c-Src expression: 
†p < 0.05, ††p < 0.01; phosphor-tyrosine expression of: §p < 0.05, §§p < 0.01 of NT vs. the indicated time points or 
treatment groups (E) siRNA-mediated PLD2 knockdown in DSS-treated HT-29 cells. NT vs. 24 h DSS + control 
siRNA treated group (**p < 0.01); 24-h DSS + control siRNA treated group vs. 24-h DSS + PLD2 siRNA-treated 
group (#p < 0.05, ##p < 0.01) (F) HT-29 colon epithelial cells were treated with 2% DSS, or 2% DSS and 1 µM 
PP2; the expression of PLD2, occludin, c- Src kinase, and p-c Src was analysed. NT vs. the 24-h DSS-treated 
group (*p < 0.05, **p < 0.01); 24-h DSS-treated group vs. 24-h DSS + PP2-treated group (#p < 0.05, ##p < 0.01). 
Uncropped western images are provided in the Supplementary Fig. S7. All data are shown as the mean ± SEM.
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inducing proteasome-mediated degradation of occludin. Hence, we show that PLD2 plays a critical role in regu-
lating occludin at the post-translational level.
Post-translational regulation of occludin is dependent on its phosphorylation and may be responsible for 
occludin turnover39–41. Occludin phosphorylation affects its assembly and disassembly at the tight junctions based 
on the amino acid moiety that is being phosphorylated27, 42, 43. Increased Tyr phosphorylation of occludin is 
observed during inflammation, resulting in the loss of interaction with other tight junction components, disso-
ciation from the membrane, and subsequent proteasome-mediated degradation28, 44, 45. Here, we observed that 
treatment with DSS induced tyrosine phosphorylation of occludin. Treatment with DSS induced the dissociation 
Figure 6. Chemical inhibitor of PLD2 phenocopies the effect of PLD2 knockout in intestinal epithelial cells 
and protects mice from DSS-induced colitis. (A) C57BL/6 mice were injected with 10 mg/kg of PLD2 inhibitor, 
VU0364739. HCl, every other day, thrice, before the start of the DSS treatment, and during the DSS treatment 
for the indicated times. Body weights of the control groups, DSS-treated, and PLD2 inhibitor-treated mice 
were monitored every day and plotted as the percentage of change in body weight. (B) Gross imaging of 
colons from the control groups, DSS-treated, and DSS + PLD2 inhibitor-treated mice. (C) Colon lengths of 
the control groups, DSS-treated, and DSS + PLD2 inhibitor-treated mice. (D) The mice were scored using 
clinical phenotypes such as stool consistency and rectal bleeding. (E) Histological score of H&E-stained colon 
histograms. (F) H&E-stained colon sections from the control, DSS-treated, and DSS + PLD2 inhibitor-treated 
mice, showing damage to the intestinal epithelial layer. Scale bar: 200 µm, 20 µm. All data are shown as the 
mean ± SEM. *p < 0.05, **p < 0.01.
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of occludin from the membrane in Caco2 monolayer cultures, a possible result of increased phosphorylation, 
which was rescued by the inhibition of Pld2. Several kinases, including c-Src and protein kinase C (PKC) iso-
forms, induce phosphorylation of occludin and disruption of tight junctions31, 46. Expression of the c-Src kinase 
increased significantly after treatment with DSS, which is mediated by PLD2 and is responsible for the phospho-
rylation of occludin. In colon epithelial cells, the inhibitor of Src kinase rescued degradation of occludin in the 
presence of DSS, indicating that c-Src plays a role in phosphorylation-induced degradation of occludin. PLD2 is 
required for DSS-induced activation of c-Src and corresponding post-translational regulation of occludin; inhi-
bition of PLD2 reduces the DSS-induced activation of c-Src and downregulation of occludin (Fig. 7). Samak et al. 
has recently shown that the DSS-induced increase in the intracellular calcium levels affects the upstream signal-
ling involved in JNK-mediated c-Src activation in colon epithelial cells47. In this study, we focused on the specific 
role of intestinal epithelial PLD2 in the regulation of tight junctions via the c-Src kinase-dependent pathway. It is 
likely that these two pathways are interconnected via activation of c-Src kinase. However, PLD2 is indispensable 
for the DSS-induced activation of c-Src; inhibition of PLD2 downregulates the activation of c-Src and rescues 
occludin levels during treatment with DSS. The relationship between calcium-mediated activation of c-Src, and 
c-Src activation mediated by PLD2, remains unclear, and the relationship between these two pathways has not 
been determined. Further studies are needed to understand the complex signalling pathways involved.
Alteration in tight junction proteins contributes to the onset of diarrhoea and perpetuation of inflammation in 
IBD, although it is likely not the sole reason for the development of the disease3. It is still unclear whether the loss 
of tight junction proteins is a causative factor, or a mere consequence, of the inflammatory response. Increased 
paracellular permeability is observed in patients with Crohn’s disease, indicating that the loss of tight junction 
proteins may be a predisposing factor in IBD48, 49. In this study, we show that the genetic or pharmacological 
inhibition of PLD2 restored occludin levels, alleviated the symptoms of colitis, and improved the survival rate of 
the mice. Restoration of tight junction proteins by inhibition of PLD2 may be used as a therapeutic intervention 
in patients with colitis50, 51; combining this therapy with the conventional immunosuppressant agents may be a 
promising strategy. Because the activity and level of PLD2 is involved in occludin turnover, it may also be a pre-
dictive factor in disease diagnosis and relapse. Our results suggest that intestinal epithelial-specific PLD2 medi-
ates the disease progression in DSS-induced colitis. It is also possible that inhibition of PLD2 had a systemic effect 
when injected into mice intraperitoneally, which may affect other cell types. A recent study by Zhou et al. demon-
strated the role of neutrophil PLD2 in the pathogenesis of colitis20. Increased expression of PLD2 was found in 
mouse neutrophils, after treatment with DSS, and in neutrophils from patients with colitis. Our previous study 
highlighted the role of neutrophil PLD2 in the pathogenesis of sepsis; pharmacological targeting of PLD2 effec-
tively prevented the progression of sepsis by enhancing the recruitment of neutrophils. Although we focused on 
the epithelial-specific role of PLD2 in colitis, it is plausible that the protective effect, observed in the DSS-induced 
colitis in our in-vivo PLD2 inhibition study, is a cumulative effect of PLD2 ablation in both neutrophils and 
intestinal epithelial cells. Furthermore, whether these events occur during disease progression in humans must 
be evaluated. It is still elusive how DSS induces the expression of PLD2 in intestinal epithelial cells. Although the 
DSS-induced activation of TLR52 or NF-kB can result in the activation of PLD2, further studies will help elucidate 
the detailed mechanism of DSS-induced upregulation of PLD2 in intestinal epithelial cells.
Figure 7. Mechanism of epithelial barrier integrity regulation by PLD2. DSS treatment upregulates the 
expression of PLD2 in colon epithelial cells, which activates c-SRC. c-SRC is a tyrosine kinase that interacts with 
the tight junction protein occludin. Activated c-Src phosphorylates occludin at the tyrosine residues and targets 
it for proteasome-mediated degradation. Dissociation of occludin from the membrane causes an increase in 
barrier permeability, which leads to increased inflammation. Graphical illustration was drawn using the images 
from Servier Medical Art by Servier with slight modifications (http://www.servier.com/Powerpoint-image-
bank, https://creativecommons.org/licenses/by/3.0/).
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Methods
Animals. All animals were housed in an animal facility at the Pohang University of Science and Technology 
(POSTECH). All experiments, including animal experiments, adhered to the ethical and institutional guide-
lines of the Pohang University of Science and Technology, (POSTECH), Pohang, South Korea, and were 
approved by the institutional ethical committee review board (approval number: POSTECH-2014-0005, 
POSTECH-2016-0014). Specific pathogen-free Villin-Cre mice (on the C57BL/6 genetic background) were pur-
chased from the Jackson Laboratory. Pld2 floxed mice were generated as previously described53. The Pld2 IEC 
KO mice were generated by breeding Pld2fl/fl mice with Villin-Cre mice. The mice used in each experiment were 
backcrossed to C57BL/6 for at least 14 generations.
Development of DSS-induced colitis. Age- and sex-matched Pld2 IEC KO mice, and their floxed lit-
termates (control mice), were co-housed before and during the experiments to avoid any differences in the gut 
microbiota. Pld2 IEC-KO and control mice were administered 2% DSS (MP Biomedicals, LLC #160110) in drink-
ing water for a period of 10 days24, 54, 55. The weight of the mice was monitored for 10 consecutive days. Loss of 
weight was represented as the percentage of weight throughout the 10 days. The onset, progression, and severity 
of the disease were monitored by the frequency of diarrhoea and rectal bleeding. Each mouse was assigned a 
score, from 0–4, based on the severity of the disease. Briefly, the score was assigned based on the consistency 
of the stool (0: normal, 2: loose stool, 4: gross diarrhoea), stool blood (0: normal, 2: bloody stool, 4: gross rectal 
bleeding) and a cumulative score was recorded10, 50. The procedure was conducted at least five times with n = 5 
per group.
For the Pld2 inhibition study, C57BL/6 mice were pre-treated either with 10 mg/kg of the chemical inhibitor 
of Pld2, VU0364739.HCl (Tocris Bioscience #4171), or 2% DMSO, administered IP every other day for 6 days. 
Treatment with DSS was then continued for 10 days, as mentioned above, for both groups. The control groups 
received DMSO only or PLD2 inhibitor only, without DSS. DMSO, or the Pld2 inhibitor, was administered IP 
every other day until the end of treatment with DSS. The weight was measured for 9 days. Clinical severity of the 
disease was monitored using stool consistency and presence of blood. The experiment was repeated at least three 
times with n = 6 per group.
DNBS-induced development of colitis. Age- and sex-matched PLD2 IEC KO and control mice were 
fasted for 12 hours before being challenged with DNBS. Mice were anaesthetized using ketamine-xylazine, 
injected IP, and were then intrarectally administered 200 mg/kg DNBS in 35% ethanol. The body weight and 
clinical phenotypes of the mice were monitored daily. Each animal was assigned a score from 0–4 based on 
the severity of the disease. Briefly, the score was assigned based on stool consistency (0: normal, 2: loose stool, 
4: gross diarrhoea), blood in stool (0: normal, 2: bloody stool, 4: gross rectal bleeding), and a cumulative score 
was recorded10, 50. Mice were sacrificed on day 4 after the DNBS challenge and the colons were dissected. Colon 
length and morphology were compared, and tissues were prepared for histological sectioning. The experiment 
was repeated three times with n = 6 per group.
Colon histopathology. After treatment with DSS, the mice were sacrificed using CO2, and the entire large 
intestine was removed. The length of each colon was measured starting from the end of the cecum to the rec-
tum. Colon tissue was rolled into a Swiss roll, fixed in 4% paraformaldehyde, and embedded in paraffin56, 57. 
Tissue sections were stained with hematoxylin and eosin and scored using blinded analysis. Histology scores, 
ranging from 0–4, were assigned based on the infiltration of immune cells, loss of goblet cells, epithelial damage, 
extent of disease, and percentage of tissue having colon inflammation. Inflammation and epithelial damage were 
scored separately, and a combined score was assigned to each mouse. Inflammation was scored as follows: 0: no 
inflammation; 1: infiltration around crypt base; 2: infiltration into mucosa; 3: extensive mucosal infiltration and 
oedema; 4: immune cell infiltration into sub mucosa. Epithelial damage was scored as follows: 0: intact epithelia; 
1: slight loss of goblet cells; 2: considerable loss of goblet cells and slight loss of intestinal crypts; 3: extensive loss 
of intestinal crypts58, 59. The extent of damage was scored as follows: 0: none; 1: extends into mucosa; 2: damage 
in mucosa and submucosa; 3: transmural. The percentage of colon tissue with colitis was scored as follows: 1: 
1–25%; 2: 26–50%; 3: 51–75%; 4: 76–100%59. Histological scores were assigned to each animal and a cumulative 
score was calculated.
In-vivo assay of intestinal permeability. The in-vivo intestinal permeability was measured using the 
FITC-dextran assay as previously described60–62. Mice, administered 2% DSS for 6 days, were fasted 6 hours before 
the procedures; 400 mg/kg FITC-dextran (Sigma Aldrich #46944) was administered by oral gavage. Blood sam-
ples were obtained via retro-orbital bleeding 4 hours after FITC-dextran gavage, and fluorescence intensity in 
the serum was measured at an excitation wavelength of 490 nm, and emission wavelength of 530 nm, using a 
spectrofluorometer (Cary Eclipse Fluorescence Spectrophotometer, Varian). FITC-dextran, diluted in phosphate 
buffered saline (PBS), was used to plot a standard curve, and the serum concentration of FITC-dextran was cal-
culated. The procedure was conducted a minimum of three times with n = 5 per group.
Isolation of colon epithelial cells. The entire colon was dissected out and cut longitudinally. The faeces 
were removed, and the lumen was cleaned with PBS. The colon was then cut into 1 cm long pieces, transferred 
into a 50 mL conical flask containing PBS, and stirred vigorously at 37 °C for 30 minutes. The tissue was then 
strained through a tea strainer, and the debris was washed in PBS to isolate any residual epithelial cells. The 
collected PBS solution was centrifuged at 3000 rpm for 5 min. The cells were then diluted in 1 mL FACS buffer, 
added to a Percoll gradient (40% and 25% Percoll solution), and subjected to density gradient centrifugation for 
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25–30 min. Then, the cells at the interface were collected, washed twice with PBS, and used for isolation of RNA 
or preparation of protein samples.
Immunohistochemistry. Paraformaldehyde-fixed, paraffin-embedded tissue sections were stained using 
a Vectastain kit (#PK-6161, Vector Laboratories, Inc.). After the removal of paraffin and dehydration, the tissue 
sections were washed in PBS and endogenous peroxidase activity was quenched using 0.3% H2O2. Sections were 
blocked with 5% horse serum diluted in PBST (0.02% Tween 20 in PBS) and incubated with the primary antibody 
against occludin (ab31721, rabbit anti-occludin, Abcam) overnight at 4 °C. Sections were then washed in PBST 
and incubated with the biotinylated secondary antibody for 2 hours at 25 °C. An avidin-biotinylated enzyme 
complex was then added, and sections were visualized using 3,3′-diaminobenzidine (DAB)-H2O2 followed by 
hematoxylin and eosin counterstaining. A fluorescent-labelled secondary antibody was used for fluorescence 
staining. Nuclear staining was performed using 4″,6′-diaminido-2-phenylindole and visualized under a Leica 
DM750 light microscope. (Leica Microsystems, Wetzlar, Germany).
Immunocytochemistry. Caco-2 cells were cultured using high glucose Dulbecco’s Modified Eagle’s 
Medium (DMEM) supplemented with 10% foetal bovine serum (FBS), 1% nonessential amino acids, 4.5 g/L 
D-glucose, 110 mg/L sodium pyruvate, and 1% antibiotic cocktail. Cells were grown until confluence, on cover 
slips coated with collagen, and then treated with 2% DSS or a combination of 2% DSS and 100 nM Pld2 inhibitor 
(VU0364739.HCl, Tocris). The control group received either DMSO or PLD2 inhibitor alone without DSS. After 
12 hours of DSS treatment, the cells were fixed using 4% paraformaldehyde for 20 min at 25 °C. Cells were then 
washed with PBS and permeabilized with 0.1% Triton X-100 diluted in PBS for 15 min at room temperature. After 
permeabilization, the cells were washed with PBS and incubated with 5% goat serum for 1 hour at room temper-
ature, followed by incubation with primary antibody against occludin (ab31721, rabbit anti-occludin, Abcam) 
overnight at 4 °C. Alexa 594-labelled anti-rabbit IgG was used as the secondary antibody. Nuclear staining was 
performed using 4″,6′-diaminido-2-phenylindole. The sections were analysed using digital micrographs and an 
LSM 700 ZEISS laser scanning confocal microscope (Carl Zeiss, Jena, Germany).
In-vitro permeability assay. In-vitro permeability was determined by measuring the flow of FITC-dextran 
across the apico-basolateral layer in a Caco-2 monolayer cell culture. Caco-2 cells were cultured on collagen 
coated 12-well chamber inserts using DMEM supplemented with 10% FBS, 4 mM glutamine, 1% nonessential 
amino acids, 4.5 g/L D-glucose, 110 mg/L sodium pyruvate, and 1% antibiotic cocktail63, 64. Cells were allowed to 
differentiate for 3 weeks. The media were replaced every 2 days. Monolayer formation was verified by measur-
ing the trans-epithelial electrical resistance65, 66 using the Millicell ERS-2 epithelial cell volt-ohm meter (Merck 
Millipore). Once the trans-epithelial resistance reached a plateau, the cells were considered differentiated and 
having formed a tight monolayer. Caco-2 monolayers were treated with 2% DSS, or 2% DSS and the Pld2 inhib-
itor. Untreated cells and PLD2 inhibitor-treated cells (without DSS) were used as controls. After 24 hours, the 
apical chamber was washed with HBSS solution, and 1 mg/mL FITC-dextran was added to the apical chamber 
(0-hour time point). After 6 hours, 100 μl media were collected from the basal chamber, and fluorescence inten-
sity, at an excitation of 490 nm and emission of 530 nm, was measured in each sample using a spectrofluorometer. 
The concentration of FITC-dextran in the sample was calculated using a standard curve of FITC-dextran.
Transfection of siRNA and DNA vectors into HT-29 colon epithelial cells. HT-29 colon epithelial 
cells were cultured in RPMI, supplemented with 10% FBS, as described above. The cells were then transfected 
with 2 µg control, or Pld2 overexpression vectors, using Lipofectamine™ 2000 (Invitrogen), and lysed after 12, 24, 
48, or 72 hours to measure the expression of PLD2 and occludin using western blotting.
For siRNA transfection, HT-29 and Caco-2 cells were grown until 40% confluence. The cells were then trans-
fected with 20 pmol of scrambled, or PLD2-specific siRNA, using Lipofectamine and RNAImax transfection rea-
gents (Invitrogen). DSS was administered for 48 hours after the transfection of siRNA, and the cells were lysed 
at the indicated time points after treatment with DSS. The cells were then lysed using lysis buffer and used for 
western blotting.
Immunoblotting. Colon tissue samples, and HT-29 cells, were treated with a lysis buffer (20 mM Tris –pH 
8, 150 mM NaCl, 1 mM EGTA, 1 mM MgCl2, 1% deoxycholate, 10 mM glycerophosphate, and 10 mM pyrophos-
phate) supplemented with a protease inhibitor cocktail. Protein samples (10 μg) were then separated on a gradient 
SDS_PAGE (6–16%) and transferred to a nitrocellulose membrane. Membranes were incubated with the follow-
ing antibodies; rabbit anti-PLD2 (PLD2 was detected using a polyclonal antibody as previously described)67, rab-
bit anti-occludin (ab31721, Abcam), rabbit anti-cSrc (sc-19, Santa Cruz Biotechnology Inc.), rabbit anti-phospho 
c-Src (#2101, Cell Signaling Technology), mouse anti-phospho tyrosine (sc-508, Santa Cruz Biotechnology Inc.), 
and mouse anti-β actin (691001, MP Biomedicals). The nitrocellulose membranes were washed and incubated 
with the corresponding peroxidase-labelled secondary antibodies (anti-rabbit IgG #074-1506, anti-mouse IgG 
#074-1806, Kirkegaard & Perry Laboratories, Inc.), and the signal was detected using the Pierce ECL Western 
Blotting Substrate (#32106 Thermo Scientific).
Statistical Analysis. All experiments were conducted at least three times and data are represented as 
mean ± SEM. Statistical significance was calculated using two-tailed Student’s t-test, or ANOVA with Dunnett’s 
multiple comparison correction, where two or more groups were compared. p < 0.05 was considered statistically 
significant. The Graph Pad Prism software was used to calculate and plot the Kaplan-Meier survival rate of mice 
after treatment with DSS, and significance was assessed using a two-way ANOVA.
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